Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"
Astellas Pharma (OTC:ALPMY) has partnered with Korea's Institute of Startup and Entrepreneurship Development (KISED) to operate the Partnership with Global Companies Program. As the first Japanese pharmaceutical company to support this initiative, Astellas will provide Korean drug-discovery startups access to its SakuLab鈩�-Tsukuba facilities and expert consultation services.
Two Korean startups have been selected for the program: TCUBEiT Inc. (T-cell-based immunotherapy) and AAVATAR Therapeutics (AAV viral vector engineering). The partnership aims to accelerate drug discovery research and support Korean startups' global expansion, with KISED providing overall management and research funding.
Astellas Pharma (OTC:ALPMY) ha stretto una collaborazione con l'Istituto coreano per lo Sviluppo delle Startup e dell'Imprenditorialit脿 (KISED) per gestire il Programma di Partnership con Aziende Globali. In qualit脿 di prima azienda farmaceutica giapponese a sostenere questa iniziativa, Astellas offrir脿 alle startup coreane nel campo della scoperta di farmaci l'accesso alle sue strutture SakuLab鈩�-Tsukuba e servizi di consulenza specialistica.
Due startup coreane sono state selezionate per il programma: TCUBEiT Inc. (immunoterapia basata su cellule T) e AAVATAR Therapeutics (ingegneria di vettori virali AAV). La partnership mira ad accelerare la ricerca nella scoperta di farmaci e a supportare l'espansione globale delle startup coreane, con KISED che fornir脿 la gestione complessiva e il finanziamento della ricerca.
Astellas Pharma (OTC:ALPMY) se ha asociado con el Instituto Coreano de Desarrollo de Startups y Emprendimiento (KISED) para operar el Programa de Asociaci贸n con Empresas Globales. Como la primera compa帽铆a farmac茅utica japonesa en apoyar esta iniciativa, Astellas proporcionar谩 a las startups coreanas de descubrimiento de f谩rmacos acceso a sus instalaciones SakuLab鈩�-Tsukuba y servicios de consulta experta.
Dos startups coreanas han sido seleccionadas para el programa: TCUBEiT Inc. (inmunoterapia basada en c茅lulas T) y AAVATAR Therapeutics (ingenier铆a de vectores virales AAV). La asociaci贸n tiene como objetivo acelerar la investigaci贸n en descubrimiento de f谩rmacos y apoyar la expansi贸n global de las startups coreanas, con KISED proporcionando la gesti贸n general y financiamiento de investigaci贸n.
Astellas Pharma (OTC:ALPMY)電� 頃滉淡 彀届梾歆勴潵鞗�(KISED)瓿� 順戨牓頃橃棳 旮�搿滊矊 旮办梾瓿检潣 韺岉姼雱堨嫮 頂勲攴鸽灗鞚� 鞖挫榿頃╇媹雼�. 鞚� 頂勲攴鸽灗鞚� 歆�鞗愴晿電� 斓滌磮鞚� 鞚茧掣 鞝滌暯須岇偓搿滌劀, Astellas電� 頃滉淡 鞁犾暯 臧滊皽 鞀ろ儉韸胳梾霌れ棎瓴� SakuLab鈩�-Tsukuba 鞁滌劋瓿� 鞝勲 旎劋韺� 靹滊箘鞀るゼ 鞝滉车頃╇媹雼�.
鞚措矆 頂勲攴鸽灗鞐愲姅 霊� 臧滌潣 頃滉淡 鞀ろ儉韸胳梾鞚� 靹犾爼霅橃棃鞀惦媹雼�: TCUBEiT Inc. (T靹疙彫 旮半皹 氅挫棴旃橂)鞕� AAVATAR Therapeutics (AAV 氚旍澊霟� 氩№劙 鞐旍雼堨柎毵�). 鞚� 韺岉姼雱堨嫮鞚� 鞁犾暯 鞐瓣惮毳� 臧�靻嶍檾頃橁碃 頃滉淡 鞀ろ儉韸胳梾鞚� 旮�搿滊矊 歆勳稖鞚� 歆�鞗愴晿電� 瓴冹潉 氇╉憸搿� 頃橂┌, KISED臧� 鞝勲皹鞝侅澑 甏�毽檧 鞐瓣惮 鞛愱笀鞚� 鞝滉车頃╇媹雼�.
Astellas Pharma (OTC:ALPMY) s'est associ茅 脿 l'Institut cor茅en pour le d茅veloppement des startups et de l'entrepreneuriat (KISED) afin de g茅rer le Programme de partenariat avec des entreprises mondiales. En tant que premi猫re entreprise pharmaceutique japonaise 脿 soutenir cette initiative, Astellas offrira aux startups cor茅ennes sp茅cialis茅es dans la d茅couverte de m茅dicaments un acc猫s 脿 ses installations SakuLab鈩�-Tsukuba ainsi que des services de consultation d'experts.
Deux startups cor茅ennes ont 茅t茅 s茅lectionn茅es pour ce programme : TCUBEiT Inc. (immunoth茅rapie bas茅e sur les cellules T) et AAVATAR Therapeutics (ing茅nierie des vecteurs viraux AAV). Ce partenariat vise 脿 acc茅l茅rer la recherche en d茅couverte de m茅dicaments et 脿 soutenir l'expansion mondiale des startups cor茅ennes, KISED assurant la gestion globale et le financement de la recherche.
Astellas Pharma (OTC:ALPMY) hat eine Partnerschaft mit dem koreanischen Institut f眉r Startup- und Unternehmertumsentwicklung (KISED) geschlossen, um das Programm 鈥濸artnerschaft mit globalen Unternehmen鈥� zu betreiben. Als erstes japanisches Pharmaunternehmen, das diese Initiative unterst眉tzt, wird Astellas koreanischen Startups im Bereich Wirkstoffforschung Zugang zu seinen 厂补办耻尝补产鈩�-罢蝉耻办耻产补-贰颈苍谤颈肠丑迟耻苍驳别苍 und fachkundige Beratungsdienste bieten.
F眉r das Programm wurden zwei koreanische Startups ausgew盲hlt: TCUBEiT Inc. (T-Zell-basierte Immuntherapie) und AAVATAR Therapeutics (AAV-Virusvektor-Engineering). Die Partnerschaft zielt darauf ab, die Wirkstoffforschung zu beschleunigen und die globale Expansion koreanischer Startups zu unterst眉tzen, wobei KISED die Gesamtverwaltung und Forschungsfinanzierung 眉bernimmt.
- First Japanese pharmaceutical company to support Korean startup program, showing market leadership
- Access to Astellas' research facilities and expert network for selected startups
- Strategic expansion into Korean biotech ecosystem
- Minor expected financial impact for fiscal year ending March 31, 2026
- Supporting Korean Startups' Drug Discovery Research and Global Expansion -
- First Pharmaceutical Company from
Under the terms of the MoU, KISED will provide overall management and research funding for the Partnership with Global Companies Program. Astellas will provide Korean drug-discovery startups, which are selected together, with KISED with access to laboratory and office space at SakuLabTM-Tsukuba, located on the premises of the Astellas Tsukuba Research Center. Startups residing in SakuLabTM-Tsukuba will not only receive support through consultations with Astellas experts in various fields, but will also be able to accelerate their drug discovery research by leveraging networks with fellow residents and Astellas researchers.
Through this program, two Korean pharmaceutical and biotech startups鈥擳CUBEiT Inc. (a next-generation T-cell-based immunotherapy developer) and AAVATAR Therapeutics (specializing in AAV viral vector engineering technology)鈥攈ave been selected. They will begin full-scale collaboration by moving into SakuLab鈩�-Tsukuba.
Tadaaki Taniguchi, M.D., Ph.D., Chief Research & Development Officer (CRDO) of Astellas
"We are very pleased to agree on a MoU with KISED for the Operation of the Partnership with Global Companies Program. In today's world, where new drug discovery ideas and technologies are emerging one after another, Diverse perspectives, expertise and experiences are essential to turning innovative ideas and technologies into VALUE for patients. Astellas is committed to fostering innovation in collaboration with startups by providing knowledge and expertise we have gained through our research and global network. We expect that the signing of this MoU will further strengthen and accelerate drug discovery research together with Korean startups, ultimately contributing to the creation of innovative medical solutions."
Jong-pil Yoo, President of KISED
"This agreement will serve as a significant opportunity to accelerate the global expansion of promising Korean startups in the bio and pharmaceutical sectors through strategic collaboration with Astellas, a global pharmaceutical company. In particular, as new drug development requires a high level of expertise and infrastructure, this program鈥攅nabling startups to leverage Astellas' research assets and global network directly鈥攊s expected to provide substantial support for their growth. KISED will continue to strengthen its partnerships with global corporations to ensure that Korean startups can enhance their competitiveness in the global market."
The impact of this partnership on Astellas' financial results for the fiscal year ending March 31, 2026, is expected to be minor.
About Astellas
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at .
About Ministry of SMEs and Startups
The Ministry of SMEs and Startups is a central government agency in
MSS is committed to developing and implementing policies that support startup growth, promote corporate development, and strengthen the competitiveness of small businesses within the national and global markets.聽Learn more at聽
About KISED
KISED carries out strategic initiatives aimed at advancing the startup ecosystem, enabling tailored and successful startups, securing sustainable future growth engines, and realizing creative and innovative smart management. Learn more at
Cautionary Notes聽(Astellas)
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
View original content to download multimedia:
SOURCE Astellas Pharma Inc.
FAQ
What is the Partnership with Global Companies Program between Astellas and KISED?
Which Korean startups were selected for Astellas' partnership program?
How will this partnership affect Astellas (ALPMY) stock?
What benefits do Korean startups receive through Astellas' program?
Why is Astellas partnering with Korean biotech startups?
